Prediction of immunotherapy response in idiopathic membranous nephropathy using deep learning-pathological and clinical factors

Prediction of immunotherapy response in idiopathic membranous nephropathy using deep learning-pathological and clinical factors

BackgroundOwing to individual heterogeneity, patients with idiopathic membranous nephropathy (IMN) exhibit varying sensitivities to immunotherapy. This study aimed to establish and validate a model incorporating pathological and clinical features using deep learning training to evaluate the response...

Full description

Bibliographic Details
Main Authors:	Xuejiao Wei, Mengtuan Long, Zhongyu Fan, Yue Hou, Xiaoyu Zhu, Zhihui Qu, Yujun Du
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Endocrinology
Subjects:	deep learning training immunotherapy response idiopathic membranous nephropathy pathological signatures clinical factors
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1328579/full

Similar Items

Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy
by: Jinxiu Liang, et al.
Published: (2023-12-01)

Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy
by: Chen X, et al.
Published: (2022-06-01)

Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China
by: Wanyi Xu, et al.
Published: (2023-04-01)

Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?
by: Giuseppe Remuzzi, et al.
Published: (2010-01-01)

Clinical characteristics and prognosis of patients with idiopathic membranous nephropathy with kidney tubulointerstitial damage
by: Mengyao Sun, et al.
Published: (2023-12-01)

Acute kidney injury in patients with idiopathic membranous nephropathy: influencing factors and prognosis
by: Zhenzhou Li, et al.
Published: (2023-12-01)

Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience
by: Ping Chen, et al.
Published: (2023-02-01)

Immunosuppressive treatment for idiopathic membranous nephropathy: An updated network meta-analysis
by: Bao Neng, et al.
Published: (2023-01-01)

The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study
by: Liu Y, et al.
Published: (2023-05-01)

Urinary exosomal hsa_circ_0001250 as a novel diagnostic biomarker of idiopathic membranous nephropathy
by: Qianyu Li, et al.
Published: (2022-12-01)

Clinicopathological features and prognosis of idiopathic membranous nephropathy with thyroid dysfunction
by: Peiheng Wang, et al.
Published: (2023-03-01)

Integrative analysis of miRNA–mRNA network in idiopathic membranous nephropathy by bioinformatics analysis
by: Wenfang He, et al.
Published: (2021-09-01)

Efficacy and safety of two dose regimens of rituximab for idiopathic membranous nephropathy
by: Zhi-hui Tu, et al.
Published: (2024-02-01)

Traditional Chinese medicine for idiopathic membranous nephropathy: A systematic review and meta-analysis
by: Wenjun Shan, et al.
Published: (2024-04-01)

Serum metabolomics analysis reveals metabolite profile and key biomarkers of idiopathic membranous nephropathy
by: Mingjun Ye, et al.
Published: (2023-04-01)

Prognostic prediction of idiopathic membranous nephropathy using interpretable machine learning
by: Yanqin Liu, et al.
Published: (2023-12-01)

Clinicopathological and prognostic characteristics of idiopathic membranous nephropathy with dual antigen positivity
by: Lei Yang, et al.
Published: (2024-01-01)

Is There a Place for Apheresis in the Management of Idiopathic Membranous Nephropathy? A Report of Three Cases and Literature Review
by: Hamza Naciri Bennani, et al.
Published: (2024-02-01)

The Analysis of Clinicopathological Characters and Short-term Prognosis in Idiopathic Membranous Nephropathy Patients with Immunoglobulin G4 Combined with Other Different Immunoglobulin G Subtypes Deposition
by: SUN Shuaigang, SHENG Xiaoxiao, ZHANG Wenhui, TIAN Huijuan, ZHAI Yaling
Published: (2023-07-01)

Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy
by: Yan-Ni Wang, et al.
Published: (2022-05-01)

Single-cell RNA sequencing shows the immune cell landscape in the kidneys of patients with idiopathic membranous nephropathy
by: Manman Shi, et al.
Published: (2023-09-01)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
by: Lin W, et al.
Published: (2019-07-01)

Idiopathic membranous nephropathy and anti-phospholipase A2 receptor antibodies
by: Ali Nayer, et al.
Published: (2013-10-01)

Clinical Practice Guideline for Chinese Medicine in the Treatment of Idiopathic Membranous Nephropathy (2021)
by: Nephrology Branch of China Association of Chinese Medicine, Nephrology Committee of Guangdong Provincial Association of Chinese Medicine, YANG Lihong, SU Peiling, BAO Kun
Published: (2023-02-01)

Association of M-Type Phospholipase A2 Receptor Deposition in Kidney Tissue with Treatment Outcomes in Patients with Idiopathic Membranous Nephropathy
by: Xie NQ, et al.
Published: (2023-12-01)

The Association Between Serum Complement 4 and Kidney Disease Progression in Idiopathic Membranous Nephropathy: A Multicenter Retrospective Cohort Study
by: Jing Liu, et al.
Published: (2022-05-01)

Elevated plasma interleukin 21 is associated with higher probability and severity of idiopathic membranous nephropathy
by: Liu Miao, et al.
Published: (2023-06-01)

The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China
by: Hongxia Guo, et al.
Published: (2023-12-01)

Association of M-Type Phospholipase A2 Receptor Deposition in Kidney Tissue with Treatment Outcomes in Patients with Idiopathic Membranous Nephropathy [Corrigendum]
by: Xie NQ, et al.
Published: (2024-01-01)

Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients
by: Bihua Wang, et al.
Published: (2022-09-01)

Retrospective study: clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody
by: Wenkai Guo, et al.
Published: (2020-02-01)

Combination of the gut microbiota and clinical indicators as a potential index for differentiating idiopathic membranous nephropathy and minimal change disease
by: Yumin Jiang, et al.
Published: (2023-12-01)

Non-diabetic urine glucose in idiopathic membranous nephropathy
by: Lingling Liu, et al.
Published: (2022-12-01)

Containing anti-PLA2R IgG antibody induces podocyte injury in idiopathic membranous nephropathy
by: Ying Zhang, et al.
Published: (2023-12-01)

Phospholipase A2 Receptor Antibodies and Clinical Prognosis in Patients with Idiopathic Membranous Nephropathy: An Updated Systematic Review and Meta-Analysis
by: Jialing Zhang, et al.
Published: (2023-01-01)

Effects of Jian Pi Qu Shi Formula on intestinal bacterial flora in patients with idiopathic membranous nephropathy: A prospective randomized controlled trial
by: Rui Lang, et al.
Published: (2020-06-01)

Phospholipase A2 receptor (PLA2R) related membranous nephropathy - not specific for idiopathic cases any more
by: Bahar Bastani
Published: (2018-01-01)

The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy ——protocol of a multicenter, randomized control trial (SQ-AUTUMN)
by: Chuang Li, et al.
Published: (2023-04-01)

VEGFA promotes the occurrence of PLA2R-associated idiopathic membranous nephropathy by angiogenesis via the PI3K/AKT signalling pathway
by: Ben Ke, et al.
Published: (2022-09-01)

Mycophenolate mofetil versus cyclophosphamide for idiopathic membranous nephropathy; a double blind and randomized clinical trial
by: Fatemeh Hayati, et al.
Published: (2019-04-01)